Cassava Sciences Inc vs Norfolk Southern Corporation — how do they compare? Cassava Sciences Inc trades at $0.93 (market cap $47.75M), while Norfolk Southern Corporation trades at $336.24 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 1573.8× Cassava Sciences Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NSC | |
|---|---|---|
Market Cap | $47.75M | $75.15B |
Sector | Health | Technology |
52-Week High | $4.64 | $350.66 |
52-Week Low | $0.87 | $272.35 |
Enterprise Value | -$34.93M | $90.70B |
Dividend Yield | — | 1.61% |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
Norfolk Southern (NSC) trades at $334.44, up 0.15% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including three consecutive quarterly earnings beats, a net income margin of 21.02%, and robust cash flow from operations of $4.36B in 2025. Recent news highlights merger developments with Union Pacific and positive Q2 2026 results driven by freight demand.
Outlook is positive with a consensus price target of $369.67, implying upside, but risks include high valuation (P/E 28.55), merger regulatory scrutiny, and fuel cost pressures. Institutional sentiment is mixed with 43.75% buy ratings, yet hedge fund activity suggests potential momentum.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →